Implication of Pre- and Post-radiotherapy ctDNA Dynamics in Patients with Residual Triple-Negative Breast Cancer at Surgery after Neoadjuvant Chemotherapy: Findings from a Prospective Observational Study

• Published in: Cancer research and treatment Vol. 56; no. 2; pp. 531 - 537
• Main Authors: Lee, Tae Hoon, Kim, Haeyoung, Kim, Yeon Jeong, Park, Woong-Yang, Park, Won, Cho, Won Kyung, Kim, Nalee
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01.04.2024; 대한암학회
• Subjects: Biomarkers, Tumor - genetics; Circulating Tumor DNA - genetics; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local - pathology; Original; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - radiotherapy; 의학일반; Neoadjuvant therapy; Triple-negative breast neoplasms; Radiotherapy; Circulating tumor DNA
• ISSN: 1598-2998; 2005-9256; 2005-9256
• DOI: 10.4143/crt.2023.996

PurposeThis study aims to determine the association between pre- and postoperative radiotherapy (PORT) circulating tumor DNA (ctDNA) dynamics and oncological outcomes in patients with residual triple-negative breast cancer who underwent surgery after neoadjuvant chemotherapy (NAC).Materials and MethodsBetween March 2019 and July 2020, 11 nonmetastatic patients with residual disease who underwent surgery after NAC were prospectively enrolled. In each patient, tumor specimens obtained during surgery and blood samples collected at three time points during PORT (T0: pre-PORT, T1: 3 weeks after PORT, T2: 1 month after PORT) were sequenced, targeting 38 cancer-related genes. Disease-free survival (DFS) was evaluated and the association between DFS and ctDNA dynamics was analyzed.ResultsAt T0, ctDNA was detected in three (27.2%) patients. The ctDNA dynamics were as follows: two showed a decreasing ctDNA variant allele frequency (VAF) and reached zero VAF at T2, while one patient exhibited an increasing VAF during PORT and maintained an elevated VAF at T2. After a median follow-up of 48 months, two patients experienced distant metastasis without any locoregional failures. All failures occurred in patients with ctDNA positivity at T0 and a decreased VAF after PORT. The 4-year DFS rates according to the T0 ctDNA status were 67% (positive ctDNA) and 100% (negative ctDNA) (p=0.032).ConclusionMore than a quarter of the patients with residual disease after post-NAC surgery exhibited pre-PORT ctDNA positivity, and ctDNA positivity was associated with poor DFS. For patients with pre-PORT ctDNA positivity, the administration of a more effective systemic treatment should be considered.